Golidocitinib combined with PD-1 antibodies achieved a 44.3% response rate in NSCLC patients post anti-PD-1 therapy progression. The combination therapy showed a complete response rate of 23.9% and a ...
Minghui Pharmaceutical Ltd. announced it is raising $131 million in a pre-IPO financing round Aug. 7. The funds will be used to advance its cancer and inflammatory disease pipeline, which include a PD ...
JAK1 inhibitors showed superior antipruritic effects compared to IL-13 antibodies in atopic dermatitis treatment within three months. TARC levels indicated potential benefits of IL-13 antibodies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results